References
- SHOJI M, GOLDE TE, GHISO J, CHEUNG TT, ESTUS S, SHAFFER LM, CAI X-D, MCKAY DM, TlNTNER R, FRANGIONE B, YOUNKIN SG: Production of the Alzheimer amyloid |3-pro-tein by normal proteolytic processing. Science (1992) 258:126.
- HAASS C, SCHLOSSMACHER MG, HUNG AY, VIGO-PELFREY C, MELLON A, OSTASZEWSKI BL, LIEBERBURG I, Koo EH, SCHENK D, TEPLOW DB, SELKOE DJ: Amyloid B-peptide is produced by cultured cells during normal processing. Nature (1992) 359:322.
- SEUBERT P, VIGO-PELFREY C, ESCH F, LEE M, DOVEY H, DAVIS D, SINHA S, SCHLOSSMACHER M, WHALEY J, SWINDLEHURST C, MCCORMACK R, WOLFERT R, SELKOE D, LIEBERBURG I, SCHENK D: Isolation and quantification of soluble Alzheimer's p-peptide from biological fluids. Nature (1992) 359:325.
- NITSCH R, SLACK BE, WURTMAN RJ, GROWDON JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science (1992) 258:304.
- Scrip World Pharmaceutical News (1992) 1769:22.
- FARLOW M, GRACON SI, HERSHEY LA, LEWIS KW, SADOWSKY CH, DOLAN-URENO J: A con-trolled trial of Tacrine in Alzheimer's Disease. J. Am. Med. Assoc. (1992) 268:2523.
- Scrip World Pharmaceutical News (1992) 1772 and 1739: 21.
- SHUTSKE GM, PIERRAT FA, KAPPLES KJ, CORNFELDT ML, SZEWCZAK MR, HUGER FP, BORES GM, HAROUTUNIAN V, DAVIS KL: 9-Amino-l,2,3,4-tetrahydroacridin-l-ols: syn-thesis and evaluation as potential Alzheimer's Disease therapeutics. J. Med. Chem. (1989) 32:1805.
- Scrip World Pharmaceutical News (1992) 1609:24.
- WiLKERSON WW: Agents for the treatment of Alzheimer's Disease: recent patent advances January to June, 1992. Cum Opin. Thera. Patents (1992) 2:1223–1238.
- See discussion regarding the possible use of 4-aminopy-ridine, a potassium channel blocker, in the treatment of Alzheimer's Disease.
- COSTALL B, NAYLOR RJ, TYERS MB: The psy-chopharmacology of the 5-HT3 receptors. Pharmacol. Then (1990) 47(2): 181–202.
- WOODRUFF GN, FOSTER AC, WONG EHF, GILL R, KEMP JA, IVERSEN LL: Excitatory amino acids and neurodegenerative disorders: possible therapeutic indications in excitatory amino acids in health and disease. (1988) David Lodge (Ed), J Wiley & Sons.
- UNGER T, BADOER E, GANTEN D, LANG RE, RETTIG R: Brain angiotensin: pathways and pharmacology. Circulation (1988) 77(Suppl I):40.
- BARNES JM, BARNES NM, COSTALL B, HORO-WITZ ZP, NAYLOR RJ: Angiotensin II inhibits the release of pH]acetylcholine from rat en-torhinal cortex in vitro. Brain Res. (1989) 491:136.
- CARINI DJ, DUNCIA JV, ALDRICH PE, CHIU AT, JOHNSON AL, PIERCE ME, PRICE WA, SANTELLA JB, WELLS GJ, WEXLER RR, WONG PC, Yoo S-E, TIMMERMANS PBMWM: Non-peptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenyl-methyl)imidazoles as potent, orally active antihypertensives. J. Med. Chem. (1991) 34: 2525.
- COSTALL B et al.: Captopril improves basic performance and antagonizes scopolamine impairment in a mouse habituation test. Br. J. Pharmacol. (1988) 95:882P.
- COSTALL B, COUGHLAN J, HOROVITZ ZP, KELLY ME, NAYLOR RJ, TOMKINS DM: The effect of ACE inhibitors Captopril and SQ29,852 in rodent test of cognition. Phar-macol. Biochem. Behav. (1989) 33:573–579.
- JOBST KA, SMITH AD, SZATMARI M, MOLYN-EUX A, ESIRI ME, KING E, SMITH A, JACKOWSKI A, MCDONALD B, WALD N: Detection of life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet (1992) 340:1179.
- AGNIOLI A, FABBRINI G, FIORAVANTI M, MARTUCCI N: CBF and cognitive evaluation of Alzheimer-type patients before and after IMAO-B treatment: a pilot study. Eur. Neu-ropsychopharmacol. (1992) 2:31–35.
- AGARWAL SK: Protease Cathepsins - A View. Biochem. Ed. (1990) 18:67.
- BARTFAI T, FISONE G, LANGEL U: Galanin and galanin antagonists; molecular and bio-chemical perspectives. TIPS. (1992) 13:312.